MedTrace Logo

Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer

NCT06537674 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-08-05

No results posted yet for this study

Summary

This study evaluated the clinical benefits of intravenous administration of pyrotinib combined with trastuzumab subcutaneous preparation by comparing the efficacy and quality of life of intravenous administration in the treatment of HER2-positive early breast cancer

Conditions

  • HER2+ Breast Cancer

Interventions

DRUG

Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection

Group A is Trastuzumab intravenous drip,Group B is Trastuzumab Subcutaneous Injection

Sponsors & Collaborators

  • Jiangsu Famous Medical Technology Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-15
Primary Completion
2025-12-30
Completion
2026-12-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06537674 on ClinicalTrials.gov